PROK PROKIDNEY CORP

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference:

H.C. Wainwright 4th Annual Kidney Virtual Conference

Date:Monday, July 14, 2025
Time:1:30pm ET
Format:Fireside Chat
Webcast:



The live webcast will be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at . Investors interested in one-on-one meetings should contact their H.C. Wainwright representative.

About ProKidney Corp.

ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit .

Investor Contacts:

ProKidney

Ethan Holdaway





LifeSci Advisors, LLC

Daniel Ferry



EN
09/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PROKIDNEY CORP

 PRESS RELEASE

ProKidney Reports Second Quarter 2025 Financial Results and Provides R...

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates FDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with type 2 diabetes and advanced CKD; FDA also confirmed that the ongoing Phase 3 PROACT 1 study may be used to support both accelerated and confirmatory approval of rilparencelMore than half of the patients required for the accelerated approval analysis using eGFR slope have been enrolled in the Phase 3 PRO...

 PRESS RELEASE

ProKidney Announces Alignment with the FDA on the Accelerated Approval...

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for both accelerated approval and for full approvalNearly half of the patients required for the accelerated approval analysis using eGFR slope have been enrolledTopline data to support an application for accelerated approval is anticipated in Q2 2027 WINSTON-SALEM, N.C., July 15, ...

 PRESS RELEASE

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virt...

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference: H.C. Wainwright 4th Annual Kidney Virtual ConferenceDate:Monday, July 14, 2025Time:1:30pm ETFormat:Fireside ChatWebcast: The live webc...

 PRESS RELEASE

ProKidney Reports Statistically and Clinically Significant Topline Res...

ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney Week as a late-breaking clinical trialIn Group 1 (n=24), kidney function stabilized in patients randomized to receive two rilparencel injections (one in each kidney). The annual decline in eGFR slope improved by 78% from -5.8 mL/min/1.73m2 in the pre-injection period to -1.3 mL/min/1.73m2 in the pe...

 PRESS RELEASE

ProKidney Corp. Completes Domestication from the Cayman Islands to Del...

ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware WINSTON-SALEM, N.C., July 01, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the completion of the domestication process to change the jurisdiction of incorporation of the Company from the Cayman Islands to Delaware. The domestication was approved by shareholders of the Company at its Annual General Meeting held on May 29, 2025. Effective as of July 1, 2025, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch